CNO Financial Group Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw all director nominees elected, executive compensation approved, and the accounting firm ratified. Strong 2025 results included double-digit earnings and sales growth, with a focus on continued profitability and ROE expansion through 2027.
-
Operating EPS rose 33% year-over-year, with strong sales and agent growth across divisions. ROE reached 13.1%, and capital position remains robust. Guidance for 2026 is affirmed, with expectations to raise ROE targets for 2027.
Fiscal Year 2025
-
Record sales and earnings growth exceeded 2025 guidance, with strong performance across both consumer and worksite divisions. Operating ROE improved to 11.4%, and 2026 guidance targets further EPS and ROE growth amid macroeconomic headwinds and ongoing tech investments.
-
Strong Q3 results featured record new annualized premiums, double-digit sales growth, and a 16% rise in operating EPS. Strategic actions include exiting the fee services business and executing a second Bermuda reinsurance treaty, both expected to boost ROE and future earnings.
-
Strong growth in life, health, and annuity sales is driven by a resilient, multi-channel distribution model and a focus on developing agents into financial advisors. Wealth management and cross-selling are expanding, with secular trends and digital strategies supporting future momentum.
-
Record new annualized premiums and strong double-digit sales growth drove robust operating earnings and ROE improvement. Investment income and book value per share increased, while capital and liquidity remained above targets. Guidance for 2025 was reaffirmed.
-
Operating earnings per share rose sharply year-over-year, driven by strong sales, investment income, and disciplined capital management. Guidance for 2025 and long-term ROE improvement was reaffirmed despite macroeconomic uncertainty, with robust segment growth and continued share buybacks.
Fiscal Year 2024
-
Exceptional Q4 and full-year 2024 results featured record sales, strong earnings growth, and robust capital returns. Guidance calls for continued ROE expansion, significant technology investments, and sustained sales momentum across divisions.
-
Operating earnings per share rose 26% year-over-year, driven by strong sales, investment income, and disciplined capital management. Guidance for 2024 EPS and excess cash flow was raised, with robust segment growth and continued focus on ROE improvement.
-
The company has successfully transitioned to a growth-focused model, emphasizing the middle market and leveraging a unique mix of products and distribution channels. Recent efficiency initiatives, strong agent productivity, and disciplined capital deployment support ongoing growth and profitability.
-
Q2 2024 saw robust earnings and sales growth, with operating EPS up 94% and strong performance across all business segments. Guidance for full-year operating EPS and excess cash flow was raised, reflecting favorable investment yields, margin expansion, and stable economic conditions.